Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321896001> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2321896001 abstract "Background: Both progression-free survival (PFS) and response rate (RR) are significantly improved when bevacizumab (Bev) is combined with first-line chemotherapy for locally recurrent/metastatic breast cancer (LR/mBC), as demonstrated in three randomized, phase III trials (E2100, AVADO, RIBBON-1). The benefit derived from Bev appears to be similar in triple-negative (TN) and non-TN LR/mBC according to subanalyses of the randomized trials. We conducted a subpopulation analysis of TN patients treated with first-line Bev-paclitaxel (Pac) in a large German observational study in the context of routine oncology practice. Methods: Patients with HER2-negative LR/mBC received first-line Bev-Pac according to the European label at the time of study design. Safety and efficacy data were collected for up to 1 year (or until progression, death, or Bev discontinuation if earlier). The endpoints were safety and efficacy (PFS and RR). We conducted an exploratory analysis of the subset of patients with TN disease. Results: Of the 567 patients for whom data are currently available, 115 (20%) had TN disease. Baseline characteristics and efficacy are summarized below. Overall survival data are immature and follow-up is continuing. Conclusions: In this ongoing study, first-line Bev-Pac demonstrated a 51% RR and median PFS of 7.7 months in patients with TN LR/mBC. These data are consistent with findings from retrospective analyses of randomized phase III trials and a subpopulation analysis of the ATHENA study. Prospective trials evaluating Bev combination regimens in TN breast cancer are ongoing. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-16-12." @default.
- W2321896001 created "2016-06-24" @default.
- W2321896001 creator A5010113967 @default.
- W2321896001 creator A5011620897 @default.
- W2321896001 creator A5014772212 @default.
- W2321896001 creator A5014911492 @default.
- W2321896001 creator A5035155822 @default.
- W2321896001 creator A5036531617 @default.
- W2321896001 creator A5051887011 @default.
- W2321896001 creator A5061433989 @default.
- W2321896001 creator A5072762948 @default.
- W2321896001 creator A5079131840 @default.
- W2321896001 creator A5084971173 @default.
- W2321896001 creator A5089392438 @default.
- W2321896001 creator A5090984572 @default.
- W2321896001 date "2010-12-15" @default.
- W2321896001 modified "2023-09-27" @default.
- W2321896001 title "Abstract P2-16-12: First-Line Bevacizumab Combined with Paclitaxel in Triple-Negative Locally Recurrent/Metastatic Breast Cancer: Subpopulation Analysis of 115 Patients Treated in Routine Oncology Practice in Germany" @default.
- W2321896001 doi "https://doi.org/10.1158/0008-5472.sabcs10-p2-16-12" @default.
- W2321896001 hasPublicationYear "2010" @default.
- W2321896001 type Work @default.
- W2321896001 sameAs 2321896001 @default.
- W2321896001 citedByCount "0" @default.
- W2321896001 crossrefType "proceedings-article" @default.
- W2321896001 hasAuthorship W2321896001A5010113967 @default.
- W2321896001 hasAuthorship W2321896001A5011620897 @default.
- W2321896001 hasAuthorship W2321896001A5014772212 @default.
- W2321896001 hasAuthorship W2321896001A5014911492 @default.
- W2321896001 hasAuthorship W2321896001A5035155822 @default.
- W2321896001 hasAuthorship W2321896001A5036531617 @default.
- W2321896001 hasAuthorship W2321896001A5051887011 @default.
- W2321896001 hasAuthorship W2321896001A5061433989 @default.
- W2321896001 hasAuthorship W2321896001A5072762948 @default.
- W2321896001 hasAuthorship W2321896001A5079131840 @default.
- W2321896001 hasAuthorship W2321896001A5084971173 @default.
- W2321896001 hasAuthorship W2321896001A5089392438 @default.
- W2321896001 hasAuthorship W2321896001A5090984572 @default.
- W2321896001 hasConcept C121608353 @default.
- W2321896001 hasConcept C126322002 @default.
- W2321896001 hasConcept C143998085 @default.
- W2321896001 hasConcept C151730666 @default.
- W2321896001 hasConcept C2775930923 @default.
- W2321896001 hasConcept C2776694085 @default.
- W2321896001 hasConcept C2777802072 @default.
- W2321896001 hasConcept C2778715236 @default.
- W2321896001 hasConcept C2779343474 @default.
- W2321896001 hasConcept C2780739268 @default.
- W2321896001 hasConcept C530470458 @default.
- W2321896001 hasConcept C71924100 @default.
- W2321896001 hasConcept C86803240 @default.
- W2321896001 hasConceptScore W2321896001C121608353 @default.
- W2321896001 hasConceptScore W2321896001C126322002 @default.
- W2321896001 hasConceptScore W2321896001C143998085 @default.
- W2321896001 hasConceptScore W2321896001C151730666 @default.
- W2321896001 hasConceptScore W2321896001C2775930923 @default.
- W2321896001 hasConceptScore W2321896001C2776694085 @default.
- W2321896001 hasConceptScore W2321896001C2777802072 @default.
- W2321896001 hasConceptScore W2321896001C2778715236 @default.
- W2321896001 hasConceptScore W2321896001C2779343474 @default.
- W2321896001 hasConceptScore W2321896001C2780739268 @default.
- W2321896001 hasConceptScore W2321896001C530470458 @default.
- W2321896001 hasConceptScore W2321896001C71924100 @default.
- W2321896001 hasConceptScore W2321896001C86803240 @default.
- W2321896001 hasLocation W23218960011 @default.
- W2321896001 hasOpenAccess W2321896001 @default.
- W2321896001 hasPrimaryLocation W23218960011 @default.
- W2321896001 isParatext "false" @default.
- W2321896001 isRetracted "false" @default.
- W2321896001 magId "2321896001" @default.
- W2321896001 workType "article" @default.